| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 34.80 | 3.7% |
| Total Income | 34.80 | 3.7% |
| Expenditure | 29.23 | 17.1% |
| PBT | 4.38 | 43.3% |
| Net Profit | 3.09 | 46.6% |
| OPM | 16.00% | 9.62pp |
| NPM | 8.88% | 8.37pp |
| EPS | 0.14 | 44.0% |
NRC Health Reports Q1 2026 Revenue Up 4% to $34.8M, TRCV Up 13%
29 Apr 2026 · 29 Apr, 1:43 am
Summary
NRC Health reported a strong start to 2026, with first-quarter revenue increasing 4% year-over-year to $34.8 million, marking its first year-over-year revenue growth since 2023. Total Recurring Contract Value (TRCV) also saw significant growth, rising 13% to $152.1 million. The company achieved a GAAP net income of $3.2 million and an Adjusted EBITDA of $9.4 million, representing a 27% margin. CEO Trent Green highlighted tangible momentum, including record TRCV, multi-year highs in new sales and customer retention, and the signing of the largest deal in the company's history, validating their strategy.
Key Highlights
- 1
NRC Health's Total Recurring Contract Value (TRCV) increased by 13% year-over-year to $152.1 million, marking its sixth consecutive quarter of sequential growth.
- 2
Total revenue for the first quarter of 2026 reached $34.8 million, representing a 4% increase from the prior year and the first year-over-year revenue growth since 2023.
- 3
GAAP net income for Q1 2026 was $3.2 million, or $0.14 per fully diluted share, while Adjusted Net Income stood at $4.6 million, or $0.21 per diluted share.
- 4
Adjusted EBITDA for the quarter was $9.4 million, achieving a 27% margin on revenue.
- 5
Net cash flow from operating activities increased by 8% year-over-year to $7.2 million, with Free Cash Flow at $5.4 million, representing 15% of revenue.
- 6
The company's Board of Directors declared a quarterly cash dividend of $0.16 per share, payable on July 10, 2026.
- 7
NRC Health achieved multi-year highs in new sales and customer retention, including signing the largest deal in its 45-year history.
Management Comments
Trent Green
We delivered a strong start to 2026, with record Total Recurring Contract Value and our first quarter of year-over-year revenue growth since 2023, reflecting the tangible momentum building across our business. The signing of the largest deal in our 45-year history is a powerful validation of our strategy and the differentiated value we deliver to health systems navigating an increasingly complex environment. Our new sales and customer retention both reached multi-year highs this quarter, underscoring the trust our customers place in us. As we look ahead, we remain committed to evolving from a measurement partner to a true outcomes driver, helping healthcare organizations turn Human Understanding into measurable, repeatable improvement.
Informational and educational content only. Not investment advice.